CANADA LIFE ASSURANCE Co Raises Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CANADA LIFE ASSURANCE Co boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 697,977 shares of the company’s stock after buying an additional 126,425 shares during the quarter. CANADA LIFE ASSURANCE Co owned 0.06% of Teva Pharmaceutical Industries worth $15,371,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TEVA. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $58,243,000. Marshall Wace LLP grew its stake in shares of Teva Pharmaceutical Industries by 87.8% in the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock valued at $113,625,000 after buying an additional 2,410,420 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $38,914,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $13.61 on Monday. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $15.43 billion, a PE ratio of -9.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The business’s fifty day moving average price is $15.45 and its 200 day moving average price is $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEVA. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Monday, April 14th. Finally, UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.